SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycles as a new class of therapies, today announced two executive appointments as it continues to advance its MXMO macrocycle discovery platform and its oncology pipeline.

加利福尼亚州南旧金山——（商业新闻短讯）——Circle Pharma，Inc.，一家临床阶段的生物制药公司，致力于发现和开发细胞渗透性大环化合物作为一种新的治疗方法，今天宣布任命两名高管，继续推进其MXMO大环化合物发现平台及其肿瘤学管道。

Marie Evangelista, Ph.D., has been appointed Senior Vice President and Head of Cancer Biology, while Constantine Kreatsoulas, Ph.D., has been promoted to Senior Vice President and Head of Discovery Technology Sciences. These appointments align with Circle’s investments in its pipeline of macrocycle therapies, including its lead program, CID-078, currently being evaluated in a Phase 1 clinical trial in solid tumors..

玛丽·伊万格丽斯塔（MarieEvangelista）博士被任命为高级副总裁兼癌症生物学负责人，而康斯坦丁·克雷特苏拉斯（ConstantineKreatsoulas）博士被提升为高级副总裁兼发现技术科学负责人。这些任命与Circle对其大环疗法管道的投资相一致，包括其领先项目CID-078，目前正在实体瘤的1期临床试验中进行评估。。

“These two senior executive appointments deepen Circle’s drug discovery expertise and scientific leadership,” said David J. Earp, JD, Ph.D., Circle’s president and CEO. “With Circle’s first oral macrocycle, CID-078, now in the clinic, we are keen to deploy our MXMO platform against a wide range of new targets as we drive to expand our pipeline.

Circle总裁兼首席执行官、法学博士大卫·J·厄普（DavidJ.Earp）表示：“这两位高管的任命加深了Circle的药物发现专业知识和科学领导力。”。。

I look forward to working closely with Marie and Constantine as they lead our discovery teams to bring more first-in-class medicines to the clinic.”.

我期待着与玛丽和康斯坦丁密切合作，因为他们带领我们的发现团队为诊所带来更多一流的药物。”。

Dr. Evangelista has more than 18 years of experience in translational oncology and small molecule drug discovery, having successfully led programs from early discovery to clinical development. Prior to joining Circle, she spent 15 years at Genentech where her leadership was instrumental in advancing Genentech’s KRAS-targeting programs.

Evangelista博士在转化肿瘤学和小分子药物发现方面拥有超过18年的经验，成功地领导了从早期发现到临床开发的项目。在加入Circle之前，她在Genentech工作了15年，她的领导在推进Genentech的KRAS目标计划方面发挥了重要作用。

Following Genentech, Dr. Evangelista held senior leadership roles at Frontier Medicines and most recently at Recursion. Dr. Evangelista holds a Ph.D. in cell and molecular biology from Queen’s University in Ontario, Canada..

继基因泰克（Genentech）之后，伊万杰利斯塔（Evangelista）博士在前沿医学（Frontier Medicines）担任高级领导职务，最近在Recursion担任高级领导职务。Evangelista博士拥有加拿大安大略省女王大学细胞与分子生物学博士学位。。

“I’m excited to join Circle at this important juncture, where its innovative macrocycle platform is translating into clinical progress,” said Dr. Evangelista. “I look forward to contributing to the development of transformative therapies for patients.”

Evangelista博士说：“我很高兴在这个重要的时刻加入Circle，其创新的大环平台正在转化为临床进展。”。“我期待着为患者的变革疗法的发展做出贡献。”

Dr. Kreatsoulas has played a pivotal role at Circle Pharma since joining in 2021, overseeing the development of the MXMO platform and contributing to the advancement of CID-078 into the clinic. Before joining Circle Pharma, he held leadership roles at GlaxoSmithKline (GSK), Merck & Co., and Bristol-Myers Squibb, with expertise in molecular design, machine learning, and computational toxicology.

自2021年加入Circle Pharma以来，Kreatsoulas博士在Circle Pharma发挥了关键作用，监督了MXMO平台的开发，并为CID-078进入临床做出了贡献。在加入Circle Pharma之前，他曾在葛兰素史克（GSK），默克公司（Merck＆Co.）和百时美施贵宝（Bristol-Myers Squibb）担任领导职务，在分子设计，机器学习和计算毒理学方面具有专业知识。

He earned his Ph.D. in Chemistry from Princeton University and a master’s degree in Regulatory Affairs and Quality Assurance from Temple University..

他在普林斯顿大学获得化学博士学位，在坦普尔大学获得监管事务和质量保证硕士学位。。

“Being a part of Circle’s evolution to a clinical-stage company has been incredibly rewarding,” said Dr. Kreatsoulas. “I am very excited to step into the role of Head of Discovery Technology Sciences as we continue to advance our ground-breaking macrocycle technologies.”

Kreatsoulas博士说：“成为Circle向临床阶段公司发展的一部分是非常有益的。”。“随着我们不断推进突破性的大环技术，我很高兴能成为发现技术科学的负责人。”

About Circle Pharma, Inc.

关于Circle Pharma，Inc。

South San Francisco-based Circle Pharma is advancing the discovery and development of intrinsically cell-permeable macrocycles that can be delivered by multiple routes, including oral administration. Circle Pharma’s MXMO™ platform combines structure-based rational drug design and advanced synthetic chemistry to develop a new generation of macrocycle therapies for challenging targets to address unmet clinical needs.

总部位于南旧金山的Circle Pharma正在推进本质上可渗透细胞的大环化合物的发现和开发，这些大环化合物可以通过多种途径递送，包括口服给药。Circle Pharma的MXMO™平台结合了基于结构的合理药物设计和先进的合成化学，开发了新一代大环疗法，以应对挑战性目标，以满足未满足的临床需求。

Circle Pharma is focusing its development efforts on cyclins, which are master regulators of the machinery that controls the progression of cells through the cell cycle and are key drivers in many cancers. The company’s lead candidate, CID-078, is currently in clinical trials as part of a growing pipeline of novel macrocycle therapeutics..

Circle Pharma将其开发工作重点放在细胞周期蛋白上，细胞周期蛋白是控制细胞在细胞周期中进展的主要调节因子，也是许多癌症的关键驱动因素。该公司的主要候选药物CID-078目前正在进行临床试验，作为不断增长的新型大环类药物管道的一部分。。

For more information, visit www.circlepharma.com.

有关更多信息，请访问www.circlepharma.com。